Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion

Prostate Cancer and Prostatic Diseases volume 8, pages 206–209 (2005)Cite this article

Abstract

Disease progression has become an important issue for the management of lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). Although several risk factors have been identified, no specific patient risk profiles have been established that can be useful in the day-to-day management of LUTS/BPH. In this study, an international panel of urologists developed a risk classification based on the attribution of a risk score to 243 unique patient profiles. From the perspective of clinical decision making, it was concluded that postvoid residual, symptom severity and maximum flow rate are the most relevant determinants of the risk of disease progression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Jacobsen SJ et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481–487.

    Article  CAS  Google Scholar 

  2. McConnell JD et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 557–563.

    Article  CAS  Google Scholar 

  3. Roehrborn CG et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53: 473–480.

    Article  CAS  Google Scholar 

  4. McConnell JD et al. Baseline measures predict the risk of benign prostatic hyperplasia clinical progression in placebo-treated patients. J Urol 2003; 169 (Suppl): 332 (Abstract 1287).

    Google Scholar 

  5. Roehrborn CG, Boyle P, Nickel JC . PSA is a significant predictor of objective parameters in men at risk of BPH progression. J Urol 2003; 169 (Suppl): 364–365 (Abstract 1362).

    Google Scholar 

  6. McConnell JD et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387–2398.

    Article  CAS  Google Scholar 

  7. Jimenez-Cruz F . Identifying patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) at risk for progression. Eur Urol Suppl 2003; 2: 6–12.

    Article  Google Scholar 

  8. Kaplan SA et al. Baseline symptoms, uroflow, and post-void residual urine as predictors of BPH clinical progression in the medically treated arms of the MTOPS trial. J Urol 2003; 169 (4 Suppl): 332–333 (Abstract 1289).

    Google Scholar 

  9. Speakman MJ et al. Integrating risk profiles in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia. A systematic analysis of expert opinion. Eur Urol Suppl 2004; 3: 61 (Abstract 233).

    Article  Google Scholar 

  10. Brook RH et al. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 1986; 2: 53–63.

    Article  CAS  Google Scholar 

  11. Meesen B . LUTS/BPH progression A literature review on risk factors for progression and impact of medical therapy on progression. Lier (Belgium), ISMAR Healthcare. 2003.

  12. Lowe F et al. Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia; a systematic analysis of expert opinion. Eur Urol Suppl 2004; 3: 39 (Abstract 147).

    Article  Google Scholar 

  13. Djavan B, Nickel JC, de la Rosette J, Abrams P . The urologist view of BPH progression: results of an international survey. Eur Urol 2002; 41: 490–496.

    Article  CAS  Google Scholar 

  14. McNicholas T . LUTS, the case is altered. Eur Urol Suppl 2002; 1: 28–35.

    Article  Google Scholar 

Download references

Acknowledgements

This study was supported by an unrestricted educational grant from Boehringer Ingelheim GmbH.

Author information

Authors and Affiliations

  1. St Luke's-Roosevelt Hospital Center, New York, NY, USA

    F C Lowe

  2. Fundacion Puigvert/ CM Teknon, Barcelona, Spain

    J Batista

  3. PAN-Klinik am Neumarkt, Cologne, Germany

    R Berges

  4. GH Pitié-Salpétrière, Paris, France

    E Chartier-Kastler

  5. Ospedale S. Anna, Como, Italy

    G Conti

  6. CHU Saint Louis, Paris, France

    F Desgrandchamps

  7. Zentralkrankenhaus St-Juergenstrasse, Bremen, Germany

    K Dreikorn

  8. Brigham & Women's Hospital, Boston, Massachusettes, USA

    M O'Leary

  9. Medical Sciences University of the São Paulo Santa Casa Hospital, São Paulo, Brazil

    M Perez

  10. Taunton & Somerset Hospital, Taunton, UK

    M Speakman

  11. University of Toronto & Princess Margaret Hospital, Toronto, Canada

    J Trachtenberg

  12. La Sapienza University, Sant'Andrea Hospital, Rome, Italy

    A Tubaro

  13. Ismar Healthcare, Lier, Belgium

    B Meesen & L Smets

  14. Erasmus University Medical Center, Rotterdam, The Netherlands

    H Stoevelaar

Authors
  1. F C Lowe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Batista
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Berges
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Chartier-Kastler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Conti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F Desgrandchamps
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K Dreikorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M O'Leary
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Perez
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Speakman
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J Trachtenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A Tubaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. B Meesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. L Smets
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. H Stoevelaar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F C Lowe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lowe, F., Batista, J., Berges, R. et al. Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion. Prostate Cancer Prostatic Dis 8, 206–209 (2005). https://doi.org/10.1038/sj.pcan.4500806

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500806

Keywords

This article is cited by

Search

Advanced search

Quick links